02564nas a2200241 4500008004100000245014200041210006900183260001400252300001200266490000700278520183200285653001102117653001802128653001902146653001702165653001502182653001302197100001802210700001802228700002102246700001902267856003602286 2025 eng d00aPhytochemical Analysis and Pro-Melanogenic Activity of Nigella sativa Extract in B16F10 Cells: A Natural Candidate for Vitiligo Treatment0 aPhytochemical Analysis and ProMelanogenic Activity of Nigella sa cJune 2025 a307-3130 v173 a

Background: Vitiligo is a chronic depigmentation disorder caused by the selective destruction of melanocytes, with limited effective treatment options, particularly in resource-limited regions. Nigella sativa (black cumin seed, BCS) has traditionally been used for various skin ailments, including pigmentation disorders. Objectives: This study aimed to evaluate the pro-melanogenic activity of a 96% ethanol extract of Indonesian BCS (EE BCS) in B16F10 cells. Methods: Phytochemical profiling was performed using gas chromatography–mass spectrometry (GC-MS), and thymoquinone (TQ) content was quantified by highperformance liquid chromatography (HPLC). Cell viability (MTT assay), tyrosinase activity (L-DOPA assay), and melanin content were measured. Results: GC-MS identified 9,12-octadecadienoic acid methyl ester (E,E) as the predominant compound (45.88%), while HPLC confirmed a relatively low TQ concentration (0.04%). EE BCS maintained >90% cell viability at concentrations up to 12.50 ppm and exhibited an IC50 of 56.41 ppm. Tyrosinase activity significantly increased at 6.25 ppm (136.40%; p < 0.05) and 12.50 ppm (228.10%; p < 0.01), accompanied by a significant elevation in melanin content (226.00%; p < 0.05 and 266.90%; p < 0.01 respectively). Conclusion: EE BCS can effectively promote melanogenesis, despite containing low levels of thymoquinone, potentially through synergistic actions of its phytochemical constituents. Given its region-specific phytochemical richness, Indonesian N. sativa extract holds promise as a natural therapeutic candidate for vitiligo. Further in-vivo and clinical validation is warranted.

10aB16F1010aMelanogenesis10aNigella sativa10aThymoquinone10aTyrosinase10aVitiligo1 aPratiwi, Dian1 aMariya, Silmi1 aRayendra, Raendi1 aSetiyono, Agus uhttps://phcogj.com/article/2505